Peripheral T-Cell Lymphoma Refractory: Clinical Trials

2 trials for Peripheral T-Cell Lymphoma Refractory, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 completed, 1 not yet recruiting. 2 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 22Completed 1, Not yet recruiting 1

Follow Peripheral T-Cell Lymphoma Refractory: new trials by email Literature Review of Peripheral T-Cell Lymphoma Refractory trials Research Report on Peripheral T-Cell Lymphoma Refractory

Trials (filtered) newest first · largest first

All 2 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Zilovertamab Vedotin and Lenalidomide (ZiVLen) Therapy for Relapsed/Refractory Peripheral T-Cell Lymphoma
Zilovertamab vedotin Intravenous (IV) Infusion - 1.75 mg/kg, Lenalidomide - Peripheral T-Cell Lymphoma Refractory
Phase 2Not yet recruitingOlivia Newton-John Cancer Research Institute252027-01-012026-11-03
Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms
Tislelizumab - Peripheral T Cell Lymphoma, PTCL
Phase 2CompletedBeiGene772018-04-132024-10-26

Narrower conditions

Recurrence (2)  ·  Immunoblastic Lymphadenopathy (1)  ·  Lymphoma, Extranodal NK-T-Cell (1)  ·  Lymphoma, Large-Cell, Anaplastic (1)  ·  Lymphoma, T-Cell (1)  ·  Lymphoma, T-Cell, Cutaneous (1)  ·  Lymphoma, T-Cell, Peripheral (1)

Broader conditions

Disease Attributes (2)  ·  Pathologic Processes (2)  ·  Pathological Conditions, Signs and Symptoms (2)  ·  Hemic and Lymphatic Diseases (1)  ·  Immune System Diseases (1)  ·  Immunoproliferative Disorders (1)  ·  Lymphadenopathy (1)  ·  Lymphatic Diseases (1)  ·  Lymphoma (1)  ·  Lymphoma, Non-Hodgkin (1)  ·  Lymphoproliferative Disorders (1)  ·  Neoplasms (1)  ·  Neoplasms by Histologic Type (1)

Interventions

Lenalidomide (1)  ·  tislelizumab (1)

Sponsors

BeiGene (1)  ·  Olivia Newton-John Cancer Research Institute (1)

Countries

Australia (1)  ·  Canada (1)  ·  China (1)  ·  France (1)  ·  Italy (1)  ·  Taiwan (1)

Top investigators

Eliza A Hawkes, MBBS DMedSc (1)

Results publications

PMID 37276067

NIH funding

2017 (1)